Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
This article was originally published in PharmAsia News
Executive Summary
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In the last installment, we took a closer look at Sanofi SA and Merck & Co., in this edition we drill down on Novo Nordisk A/S, Roche Holdings AG and GlaxoSmithKline PLC ('Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1),' PharmAsia News, Aug. 8, 2011).
You may also be interested in...
With A New CEO, Will AstraZeneca Change Its Approach In Emerging Markets?
Roche’s surging growth in China could hint at what’s coming to AstraZeneca in emerging markets as Pascal Soriot, Roche’s head of pharmaceuticals, takes over at AZ.
A Closer Look: Is Double-Digit Growth Sustainable In Emerging Markets? (Part 2 of 2)
A new debate among investors concerns whether double-digit growth is possible across emerging markets or only in China. PharmAsia News takes a closer look.
A Change Of Plans: Roche Teams Up With Emcure For Low-Cost Herceptin, Mabthera In India
The Swiss pharma has changed up its strategy in India in an effort to boost volumes.